DSIP Peptide and Sleep: What the Research Shows

Delta sleep-inducing peptide (DSIP) is not an approved sleep treatment, and the human evidence behind it is thin. It is a small peptide that researchers first studied in the 1970s and 1980s. Today it is sold online with promises of deeper sleep, and the FDA has reviewed it and found too little clinical data to support it for chronic insomnia. This article explains what the old trials found, why "research use only" vials are a problem, and what has better evidence if you are not sleeping well.

TL;DR

DSIP (also called emideltide) is not FDA-approved for any medical use, and the FDA's 2026 review found insufficient evidence that it treats chronic insomnia.
The human studies are old, small and mixed. Some reported modest changes in sleep, and others could not separate the effect from placebo.
Products sold as "research only" have not been evaluated for identity, purity, sterility or safety in people.
Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia in adults.
If sleep is a problem, a clinician can look for causes such as hormone changes, sleep apnea or medications, and that is a better starting point than a peptide.

What DSIP is and where it came from
What the human studies found
Does DSIP help with sleep? A plain answer
Approved, compounded and research-only: three different things
Questions people ask about DSIP
What has better evidence for insomnia
How to prepare for a sleep conversation with a clinician
Our perspective
Talking to a clinician through AirMedFit
FAQ
Sources

What DSIP is and where it came from

DSIP is a nine-amino-acid peptide (a nonapeptide). It was first described in rabbits and later studied in several species for its effects on sleep. A 2001 review of the peptide is one often-cited summary, and it describes DSIP as a sleep-modulating substance rather than a sedative.

The name suggests more than the science supports. "Delta" refers to slow-wave sleep, the deep stage of sleep. Whether the peptide reliably increases that stage in people is the question the research never settled. The body's own role for DSIP is also not clearly established. The synthetic version used in studies is a laboratory compound, and it is not the same as anything you can show your body makes on demand.

You may see DSIP called emideltide. That is the name the FDA uses in its documents, so it is the term to search for if you want the regulatory record.

What the human studies found

The human data comes mostly from the 1980s and early 1990s. Three studies show the pattern.

A first human study in six healthy volunteers. It looked at acute and delayed effects of DSIP on sleep under close laboratory observation. It was a very small group, so it can show that an effect is worth studying and cannot show that the effect is reliable.
A summary of insomnia investigations. This paper describes studies in which single injections given before sleep were followed by improved sleep in some people with insomnia. The dosing was weight-based and given under study conditions. It is not a guide for anyone to copy.
A double-blind study in chronic insomnia. This study of 16 patients used a matched-pairs, placebo-controlled design over five consecutive nights in a sleep laboratory. The abstract reports higher sleep efficiency and shorter time to fall asleep with DSIP than with placebo.

That last result is the one most often quoted, and it deserves a fair reading. It is a real, controlled finding. It is also a single study with 16 people over five nights, from 1992. Chronic insomnia is a long-term condition, and a five-night lab result tells you little about whether something works for months at home.

Why the FDA was not persuaded

In 2026 the FDA prepared an evaluation of emideltide for the Pharmacy Compounding Advisory Committee. The question was whether DSIP should be allowed on the list of bulk drug substances that certain pharmacies can use in compounding. The agency's review concluded there was insufficient evidence from peer-reviewed clinical data to support effectiveness for chronic insomnia, narcolepsy or opioid withdrawal. It described the older studies as small, inconclusive or limited by weak controls and blinding.

The same document makes a broader point. Compounded products do not go through the testing for identity, purity and sterility that approved drugs do. That matters for a peptide that is injected.

This article does not report how the committee voted, because we could not verify the outcome from an official FDA page. Check the FDA's compounding pages for the current status before you rely on anything you read, including here. Rules in this area have been changing.

Why the FDA was not persuaded — overview diagram

Does DSIP help with sleep? A plain answer

Nobody can say with confidence that it does. Some early studies suggest it might shorten the time to fall asleep or improve sleep efficiency. Others were weak or confounded by placebo response. No professional insomnia guideline recommends it. The honest summary is that DSIP is unproven for insomnia, and that is a different statement from "it does not work."

Two other things are not known either:

Safe dosing. There are no modern, high-quality trials that set a dose for home use. For that reason this article gives none. Numbers you see on retail sites and forums do not come from a validated standard.
Long-term safety and interactions. The FDA review points to the lack of data. If you take sleep medicines, antidepressants, opioids or anything else that affects the brain, nobody has studied how DSIP combines with them.

Approved, compounded and research-only: three different things

These terms get blurred on product pages, so it helps to separate them.

Category	What it means	DSIP status
FDA-approved drug	Reviewed for safety, effectiveness and manufacturing quality for a stated use	Not approved for any use
Compounded drug	Made by a pharmacy for an individual prescription, under rules for compounding	The FDA has evaluated it and found insufficient evidence for insomnia
"Research use only"	Sold as a laboratory chemical, not for human use	Common online, not evaluated for human safety, quality or efficacy

A facility being registered with the FDA is not the same as the product being approved. Phrases like "pharmaceutical grade" or "made in the USA" are marketing language, not regulatory findings. Some sellers also add a "telemedicine consultation" to make a product look medically supervised. Before you buy anything, ask who the prescriber is, which pharmacy fills the order, and whether you can verify both.

Our guides on which peptides are FDA-approved, the risks of research peptides and how patients can obtain peptides legally go through these distinctions in more detail. If you are tempted by an overseas supplier, read what to do about flagged overseas peptide suppliers first.

Questions people ask about DSIP

How long before bed, and how fast does it work?

There is no validated answer. The old trials gave injections under supervision in laboratory settings, and timing in those studies cannot be turned into advice for home use. Any website giving a precise timing and dose is going beyond the evidence.

Does it make you drowsy?

Some early volunteer studies reported sleepiness soon after administration, and others found weak effects. Researchers have said the effect may be modulating rather than sedating. Drowsiness is also a reason not to drive or do risky tasks if you are using any sleep-affecting substance, so talk with a clinician rather than testing it yourself.

What about recovery and injury?

Searches such as "best peptides for recovery" often lead to DSIP pages that mention recovery. The evidence for peptides in sports medicine is mostly from animals. A 2026 review of peptide supplements in sports medicine describes promising but variable findings in animal models of tendon, bone and ligament healing, with heterogeneous results. Nothing in that picture supports DSIP as a recovery tool. Our overview of what is proven and what isn't in peptide therapy covers the wider field.

What has better evidence for insomnia

For chronic insomnia in adults, the first-line treatment is not a drug. A review of chronic insomnia treatment in adults describes cognitive behavioral therapy for insomnia (CBT-I) as an effective but underused first-line treatment. CBT-I is a structured program that usually covers sleep scheduling, stimulus control and changing unhelpful thoughts about sleep. Its benefits do not depend on a drug, so it avoids the side effects of sedatives. A review of psychological treatment options supports the same approach.

When medication is appropriate, approved options exist, and a clinician chooses among them based on your situation. A clinician primer on insomnia drugs notes that the FDA has approved an orexin receptor antagonist, suvorexant, for sleep onset and maintenance problems. Another evidence review of insomnia disorder management notes that many trials were small and short, and that some drugs used for insomnia are not specifically approved for it. So even in standard care there is uncertainty, and that is a reason to have a professional weigh it with you.

Some people also want to try non-drug supports alongside CBT-I. Options such as PEMF for sleep are discussed by wellness providers, though you should ask any provider what evidence supports the device they offer.

What has better evidence for insomnia — overview diagram

Sleep problems often have a cause worth finding

Poor sleep is a symptom, and a clinician may look for what is behind it. Common candidates include sleep apnea, pain, medications, stress, alcohol and caffeine. For some people, particularly around perimenopause and menopause, hormone shifts can disturb sleep. If that is your situation, see our look at progesterone for sleep and what the evidence shows. Lab work can sometimes help your clinician decide what to check, but a test result alone does not diagnose insomnia.

How to prepare for a sleep conversation with a clinician

A short, specific visit goes further than a vague one. Before you go, gather:

Two weeks of sleep notes. Bedtime, time to fall asleep, night wakings, wake time, and how you feel in the day.
Every medicine and supplement you take. Include over-the-counter sleep aids, cannabis, alcohol and any peptide you have already bought.
Your health history. Snoring, restless legs, mood changes, pain, menopausal symptoms, or changes in weight.
Your questions. Is CBT-I available to me? Could a medical cause be involved? Which tests, if any, make sense? What are the risks of this specific treatment?
Honesty about the peptide. If you are considering DSIP, say so. A clinician cannot weigh a risk they do not know about.

Seek urgent care rather than a routine visit if sleeplessness comes with chest pain, severe mood changes or thoughts of self-harm.

Our perspective

We publish educational information about clinician consultations, hormone questions, weight management and related topics. Our view on DSIP is straightforward: the interest has run ahead of the evidence, and a sleep problem deserves a proper evaluation before an experimental compound.

We would not describe a peptide as approved, tested or effective when the FDA record says the evidence is insufficient. We also think readers are better served by knowing the difference between approved, compounded and research-only products than by a confident dose chart. If you want to explore sleep, hormones or metabolic health, the useful first step is a conversation with a licensed clinician who can review your history, order appropriate tests and tell you what is and is not supported. Treatment decisions belong to you and that clinician, and nothing here replaces that conversation.

— AirMedFit

Talking to a clinician through AirMedFit

If you want to raise a sleep or hormone question with a clinician, our Doctor's Consultation page has the details. The consultation listing shows an Async Doctor's Consult at 49 USD (one-off) and a Sync Doctor's Consult at 120 USD (one-off). If you and your clinician decide lab work is relevant, the medical services collection lists Men's Essential panels at 129 USD and Women's Essential panels at 139 USD, each one-off and with a home kit included. A consultation does not guarantee a prescription, and what a clinician recommends depends on your history. Confirm current availability, scope and follow-up on the page before you book.

FAQ

Is DSIP legal to buy?

DSIP is not FDA-approved for any medical use. It is sold online mostly as a "research use only" chemical, which means it is not labeled or evaluated for human use. Legal status for compounding is under FDA review, so check the agency's current compounding pages.

Can DSIP treat insomnia?

The FDA's 2026 evaluation found insufficient evidence that it treats chronic insomnia. A few small older trials reported modest improvements in sleep, but they were limited. Professional guidelines point to CBT-I first for chronic insomnia.

Is there a safe DSIP dose?

No standard dose has been established for home use. The older trials used supervised, weight-based injections in study settings, and those numbers should not be copied. Ask a licensed clinician about your sleep problem rather than relying on a retail dosing chart.

What should I do instead if I cannot sleep?

Start with a sleep diary and a clinician visit to look for medical causes, then ask about CBT-I. Medication can be discussed if appropriate. Seek prompt care if poor sleep comes with severe mood symptoms or chest pain.